Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]
SEC Accession No. 0001636282-24-000113
Filing Date
2024-11-18
Accepted
2024-11-18 16:09:10
Documents
77
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q/A syre-20240930.htm   iXBRL 10-Q/A 1311277
2 EX-31.1 spyre-20240930xex311a.htm EX-31.1 9607
3 EX-31.2 spyre-20240930xex312a.htm EX-31.2 9616
4 EX-32.1 spyre-20240930xex321a.htm EX-32.1 6330
  Complete submission text file 0001636282-24-000113.txt   8273517

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT syre-20240930.xsd EX-101.SCH 62326
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT syre-20240930_cal.xml EX-101.CAL 69322
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT syre-20240930_def.xml EX-101.DEF 458221
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT syre-20240930_lab.xml EX-101.LAB 651756
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT syre-20240930_pre.xml EX-101.PRE 541766
80 EXTRACTED XBRL INSTANCE DOCUMENT syre-20240930_htm.xml XML 1186895
Mailing Address 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453
Business Address 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453 6176515940
Spyre Therapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

EIN.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q/A | Act: 34 | File No.: 001-37722 | Film No.: 241471533
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)